Down-regulation of S100A9 inhibits osteosarcoma cell growth through inactivating MAPK and NF-κB signaling pathways

[1]  H. Meng,et al.  S100A9-induced release of interleukin (IL)-6 and IL-8 through toll-like receptor 4 (TLR4) in human periodontal ligament cells. , 2015, Molecular immunology.

[2]  Xing-ye Wu,et al.  Oct-4 is required for an antiapoptotic behavior of chemoresistant colorectal cancer cells enriched for cancer stem cells: effects associated with STAT3/Survivin. , 2013, Cancer letters.

[3]  D. Park,et al.  S100A8 and S100A9 promotes invasion and migration through p38 mitogen-activated protein kinase-dependent NF-κB activation in gastric cancer cells , 2013, Molecules and cells.

[4]  J. Markowitz,et al.  Review of S100A9 biology and its role in cancer. , 2013, Biochimica et biophysica acta.

[5]  M. Sakaguchi,et al.  S100A9 is a novel ligand of EMMPRIN that promotes melanoma metastasis. , 2013, Cancer research.

[6]  T. Leanderson,et al.  S100A9 and tumor growth , 2012, Oncoimmunology.

[7]  T. Leanderson,et al.  S100A9 Interaction with TLR4 Promotes Tumor Growth , 2012, PloS one.

[8]  O. Delattre,et al.  A new subtype of bone sarcoma defined by BCOR-CCNB3 gene fusion , 2012, Nature Genetics.

[9]  D. Tang,et al.  HMGB1 promotes drug resistance in osteosarcoma. , 2012, Cancer research.

[10]  G. Srikrishna.  S100A8 and S100A9: New Insights into Their Roles in Malignancy , 2011, Journal of Innate Immunity.

[11]  F. Della Ragione,et al.  Targeting p27Kip1 protein: its relevance in the therapy of human cancer , 2011, Expert opinion on therapeutic targets.

[12]  W. Chazin.  Relating form and function of EF-hand calcium binding proteins. , 2011, Accounts of chemical research.

[13]  Roy M. Williams,et al.  S100A8/A9 Activate Key Genes and Pathways in Colon Tumor Progression , 2011, Molecular Cancer Research.

[14]  S. Ferrari,et al.  Emerging drugs for high-grade osteosarcoma , 2010, Expert opinion on emerging drugs.

[15]  H. Moses,et al.  Gr-1+CD11b+ myeloid cells tip the balance of immune protection to tumor promotion in the premetastatic lung. , 2010, Cancer research.

[16]  J. Simard,et al.  Induction of neutrophil degranulation by S100A9 via a MAPK‐dependent mechanism , 2010, Journal of leukocyte biology.

[17]  S. Ostrand-Rosenberg.  Myeloid-derived suppressor cells: more mechanisms for inhibiting antitumor immunity , 2010, Cancer Immunology, Immunotherapy.

[18]  D. Bar-Sagi,et al.  Distinct populations of metastases‐enabling myeloid cells expand in the liver of mice harboring invasive and preinvasive intra‐abdominal tumor , 2010, Journal of leukocyte biology.

[19]  W. Chazin,et al.  S100A8/A9: a Janus-faced molecule in cancer therapy and tumorgenesis. , 2009, European journal of pharmacology.

[20]  P. Allavena,et al.  Cellular and molecular pathways linking inflammation and cancer. , 2009, Immunobiology.

[21]  Anindya Dutta,et al.  p21 in cancer: intricate networks and multiple activities , 2009, Nature Reviews Cancer.

[22]  R. Bukowski,et al.  Myeloid-derived suppressor cells: A novel therapeutic target , 2009, Current oncology reports.

[23]  R. Ramasamy,et al.  Receptor for AGE (RAGE) and its ligands—cast into leading roles in diabetes and the inflammatory response , 2009, Journal of Molecular Medicine.

[24]  G. Ottaviani,et al.  The epidemiology of osteosarcoma. , 2009, Cancer treatment and research.

[25]  V. Adhami,et al.  A dietary anthocyanidin delphinidin induces apoptosis of human prostate cancer PC3 cells in vitro and in vivo: involvement of nuclear factor-kappaB signaling. , 2008, Cancer research.

[26]  D. Foell,et al.  Proinflammatory S100 Proteins Regulate the Accumulation of Myeloid-Derived Suppressor Cells1 , 2008, The Journal of Immunology.

[27]  W. Nacken,et al.  Inhibition of dendritic cell differentiation and accumulation of myeloid-derived suppressor cells in cancer is regulated by S100A9 protein , 2008, The Journal of experimental medicine.

[28]  D. Foell,et al.  RAGE, carboxylated glycans and S100A8/A9 play essential roles in colitis-associated carcinogenesis , 2008, Carcinogenesis.

[29]  Herrick J Siegel,et al.  Current concepts on the surgical and medical management of osteosarcoma , 2008, Expert review of anticancer therapy.

[30]  Saeid Ghavami,et al.  S100A8/A9 at low concentration promotes tumor cell growth via RAGE ligation and MAP kinase‐dependent pathway , 2008, Journal of leukocyte biology.

[31]  J. Jones,et al.  A review of the S100 proteins in cancer. , 2008, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[32]  T. Arumugam,et al.  RAGE and RAGE ligands in cancer. , 2007, Current molecular medicine.

[33]  T. Shimo,et al.  Specific inhibitor of MEK-mediated cross-talk between ERK and p38 MAPK during differentiation of human osteosarcoma cells , 2007, Journal of Cell Communication and Signaling.

[34]  Joseph Avruch,et al.  MAP kinase pathways: the first twenty years. , 2007, Biochimica et biophysica acta.

[35]  S. Ferrari,et al.  Adjuvant and neoadjuvant combination chemotherapy for osteogenic sarcoma , 2007, Current opinion in oncology.

[36]  P. Angel,et al.  S100A8 and S100A9 in inflammation and cancer. , 2006, Biochemical pharmacology.

[37]  C. Franzius,et al.  Skip metastases in osteosarcoma: experience of the Cooperative Osteosarcoma Study Group. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[38]  H. S. Warren,et al.  Toll-like receptors. , 2005, Critical care medicine.

[39]  K. Kelsey,et al.  Interaction between the bone morphogenetic proteins and Ras/MAP-kinase signalling pathways in lung cancer , 2005, British Journal of Cancer.

[40]  Jing-Yuan Fang,et al.  The MAPK signalling pathways and colorectal cancer. , 2005, The Lancet. Oncology.

[41]  W. Nacken,et al.  The arachidonic acid‐binding protein S100A8/A9 promotes NADPH oxidase activation by interaction with p67phox and Rac‐2 , 2005, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[42]  T. Hoang‐Xuan,et al.  EMMPRIN/CD147, an MMP modulator in cancer, development and tissue repair. , 2005, Biochimie.

[43]  P. Schirmacher,et al.  Chromosome alterations in human hepatocellular carcinomas correlate with aetiology and histological grade – results of an explorative CGH meta-analysis , 2005, British Journal of Cancer.

[44]  I. Thorey,et al.  MRP8 and MRP14 control microtubule reorganization during transendothelial migration of phagocytes. , 2004, Blood.

[45]  Sakari Knuutila,et al.  Clustering of molecular alterations in gastroesophageal carcinomas. , 2004, Neoplasia.

[46]  Zhihua Liu,et al.  Discovery of Ca2+-relevant and differentiation-associated genes downregulated in esophageal squamous cell carcinoma using cDNA microarray , 2004, Oncogene.

[47]  L. Platanias.  Map kinase signaling pathways and hematologic malignancies. , 2003, Blood.

[48]  K. Vermeulen,et al.  The cell cycle: a review of regulation, deregulation and therapeutic targets in cancer , 2003, Cell proliferation.

[49]  T. Vogl,et al.  Phagocyte-specific S100 proteins: a novel group of proinflammatory molecules. , 2003, Trends in immunology.

[50]  T. Hunter,et al.  The Protein Kinase Complement of the Human Genome , 2002, Science.

[51]  S. Petersen,et al.  Chromosomal imbalances of primary and metastatic lung adenocarcinomas , 2002, The Journal of pathology.

[52]  P. Dhawan,et al.  Correction: A Novel NF-κB-inducing Kinase-MAPK Signaling Pathway Up-regulates NF-κB Activity in Melanoma Cells , 2001, The Journal of Biological Chemistry.

[53]  M. Goebeler,et al.  S100A8 and S100A9 in inflammatory diseases , 2001, The Lancet.

[54]  M. Karin,et al.  Mammalian MAP kinase signalling cascades , 2001, Nature.

[55]  M. Lackmann,et al.  S100 protein CP‐10 stimulates myeloid cell chemotaxis without activation , 1996, Journal of cellular physiology.